Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Antiaging Quantum Living (AAQL) Shares Outstanding (Diluted Average) (2022 - 2025)

Antiaging Quantum Living (AAQL) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $31.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) changed N/A to $31.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $30.0 million for FY2024, 0.0% changed from the prior year.
  • Shares Outstanding (Diluted Average) hit $31.7 million in Q4 2025 for Antiaging Quantum Living, up from $30.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $31.7 million in Q4 2025 to a low of $30.0 million in Q3 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $30.1 million across 4 years, with a median of $30.0 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): dropped 0.15% in 2024 and later increased 0.15% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $30.0 million in 2022, then changed by 0.0% to $30.0 million in 2023, then dropped by 0.15% to $30.0 million in 2024, then increased by 5.9% to $31.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for AAQL at $31.7 million in Q4 2025, $30.0 million in Q3 2025, and $30.0 million in Q2 2025.